Overactive Bladder

Association between novel inflammatory markers and overactive bladder: a cross-sectional study of NHANES 2009 to 2018.

To investigate the relationship between Overactive Bladder (OAB) and inflammatory markers, including the Systemic Immune-Inflammation Index (SII), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Inflammation Response Index (SIRI).

Comparison of efficacy and safety of mirabegron and vibegron in the treatment of Overactive Bladder (OAB) in older women: A systematic review and meta-analysis.

After the introduction of anticholinergic drugs for the treatment of overactive bladder (OAB), the discovery of β-adrenergic agonists has helped reduce the side effects associated with the former.

Revision Rates for Rechargeable Versus Non-Rechargeable Sacral Neuromodulation Devices in the Management of Overactive Bladder.

Overactive bladder (OAB) is a prevalent condition that can have a significant impact on quality of life. Sacral neuromodulation (SNM) is proven as an effective treatment option for OAB patients. Rechargeable devices have gained popularity in recent years.

A New Perspective on the Etiology of Overactive Bladder Syndrome-Could Overactive Bladder Syndrome Be Associated With Altered Perception of Somatic Sensations as a Result of Obsessive-Compulsive Disorder? A Case-Control Study.

This study aimed to investigate the potential role of obsessive-compulsive disorder (OCD), altered perception of bodily sensations, and somatization in the etiology of overactive bladder (OAB).

A total of 124 participants were included in the study.

Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study.

The COMPOSUR study is evaluating vibegron for the treatment of overactive bladder (OAB) in a real-world setting. We report results of a prespecified 6-month interim analysis, assessing patient-reported treatment satisfaction, persistence, safety, and tolerability over the first 6 months after receiving a new prescription for vibegron.

Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia.

To compare the risk of incident dementia in patients prescribed either an anticholinergic medication or mirabegron.

This was a retrospective cohort study of patients treated for OAB with pharmacotherapy between the years 2012 and 2023, using data from the TrinetX Research Collaborative Network.

The association between magnesium depletion score (MDS) and overactive bladder (OAB) among the U.S. population.

This study aimed to assess the relationship between magnesium depletion score (MDS) and overactive bladder (OAB) prevalence.

This study utilized data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018.

Transvaginal Detrusor Nerve Radiofrequency Ablation for Overactive Bladder.

Autonomic nerves and ganglia that affect bladder sensation and detrusor contractility are present below the proximal urethra and trigone. Radiofrequency energy has been shown to potentially ablate/modulate these nerves in overactive bladder (OAB) patients.

Machine Vision Augmentation to Detect Detrusor Overactivity in Overactive Bladder: A Frontier of Artificial Intelligence Application in Functional Urology-Proof of Concept Clinical Study.

Overactive bladder (OAB) is a common urological condition with increasing prevalence, especially in an aging population. Diagnosing and treating OAB can be challenging. While urodynamic study (UDS) is useful to confirm involuntary detrusor overactivity (DO), it is invasive, time-consuming, and requires good patient coordination, which limits its clinical utility.

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Overactive bladder (OAB) is a condition characterised by urinary urgency, often accompanied by frequency and nocturia. Antimuscarinics and β3 receptor agonists are first-line therapies that improve urinary symptoms and the quality of life.